Here's what we'll cover
Here's what we'll cover
If you have tried to get Ozempic, Wegovy, or Zepbound covered, you may have hit a frustrating wall. Your doctor recommends the medication, but your plan says you do not qualify yet. For many patients, not yet really means not until you are sicker.
That is not a glitch. It is how most coverage rules are written. Understanding the rules is the first step to getting help without waiting for a preventable diagnosis.
How GLP-1 Coverage Rules Work
The FDA approved weight management labels for Wegovy and Zepbound cover adults with:
- A body mass index (BMI) of 30 or higher, or
- A BMI of 27 or higher plus at least one weight related condition, such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea
Insurers often add their own layers on top of those labels: prior authorization, step therapy, proof of a supervised diet program, or higher BMI cutoffs. Ozempic and Mounjaro are approved for type 2 diabetes, so plans usually cover them only with that diagnosis. Many employer plans exclude weight loss drugs altogether, according to healthinsurance.org.
The Catch: Preventive Drugs Gated Behind the Diseases They Prevent
GLP-1 medications are increasingly understood as metabolic treatments, not just weight loss drugs. The evidence for prevention is strong:
- In the SELECT trial, semaglutide reduced heart attacks, strokes, and cardiovascular deaths by 20% in people with overweight or obesity and heart disease.
- In a three year study of adults with obesity and prediabetes, tirzepatide reduced progression to type 2 diabetes by about 94% compared with placebo.
Yet a person with a BMI of 28 and prediabetes may be denied, while the same person qualifies after developing diabetes or having a heart attack. Clinicians and patient advocates describe this pattern often. The rules reward waiting and penalize early action.
Medicare Opened a Door, With the Same Logic
Medicare Part D has long been barred from covering drugs used for weight loss alone. Since July 1, 2026, the temporary Medicare GLP-1 Bridge lets eligible Medicare Part D enrollees get Wegovy, Zepbound, or Foundayo for a $50 monthly copay through December 31, 2027. It is a real improvement, but its eligibility rules show the same sicker first design:
| BMI | Also required |
|---|---|
| 35 or higher | No additional condition |
| 30 to 34.9 | Heart failure, uncontrolled high blood pressure, or kidney disease |
| 27 to 29.9 | Prediabetes, prior heart attack, prior stroke, or peripheral artery disease |
Prior authorization is still required, and your doctor must confirm you received lifestyle counseling. Medicaid coverage still varies by state.
What Your Insurer Is Actually Doing
Prior Authorization
Your doctor submits documentation showing you meet the plan's criteria. Incomplete paperwork is one of the most common reasons for denial.
Step Therapy
Also called fail first, this requires trying cheaper options before the drug your doctor prefers.
Hard Thresholds
Cutoffs ignore context. A BMI of 26.9 with serious metabolic risk can be denied while a BMI of 31 with few risks is approved.
Formulary Exclusion
Some plans, especially self funded employer plans, leave weight management drugs off the formulary entirely.
What It Costs If You Pay Yourself
The good news is that self pay prices have fallen sharply since 2024. Typical manufacturer prices as of October 2026, as compiled by Kymata Health:
| Medication | Typical self pay monthly price | FDA approval |
|---|---|---|
| Wegovy pill | About $149 to $299 by dose | Chronic weight management |
| Wegovy pen | About $199 for initial doses, $349 at maintenance | Chronic weight management and cardiovascular risk reduction |
| Zepbound | About $299 to $449 by dose | Chronic weight management and sleep apnea |
| Ozempic | About $199 to $499 at select pharmacies | Type 2 diabetes |
Prices change often, so confirm before you buy and check GLP-1 coupons and savings programs. Self pay purchases usually do not count toward your deductible.
How to Push Back
- Get the criteria in writing. Ask your plan for its exact GLP-1 coverage policy.
- Document everything. Make sure your chart lists your BMI and every related condition, including prediabetes, sleep apnea, fatty liver disease, high blood pressure, and high cholesterol.
- Ask for a letter of medical necessity that explains your risk and the evidence for treatment.
- Appeal denials. You have the right to an internal appeal and, in most cases, an external review by an independent reviewer.
- Check your HR benefits at open enrollment and ask whether your employer will add coverage.
- Compare self pay options if coverage is not available, since manufacturer prices may now be manageable.
No waiting list. No insurance needed.
Frequently Asked Questions
Why does my insurance deny Wegovy when my doctor recommends it?
Many plans add criteria beyond the FDA label, such as higher BMI cutoffs, step therapy, or a required diabetes diagnosis, and some exclude weight loss drugs entirely. Ask for the written criteria and appeal if you meet them.
What BMI do I need to qualify for Wegovy or Zepbound?
The FDA labels cover a BMI of 30 or higher, or 27 or higher with at least one weight related condition. Your plan may set stricter rules.
Does Medicare cover GLP-1 drugs for weight loss now?
Through the Medicare GLP-1 Bridge, eligible Medicare Part D enrollees can get Wegovy, Zepbound, or Foundayo for $50 a month from July 1, 2026 to December 31, 2027. Eligibility depends on BMI and certain conditions.
Can GLP-1 medications prevent diabetes or heart disease?
Evidence says they lower risk. Semaglutide cut major cardiovascular events by 20% in SELECT, and tirzepatide reduced progression from prediabetes to type 2 diabetes by about 94% over three years.
How do I appeal a GLP-1 coverage denial?
Request the denial reason in writing, have your doctor submit a letter of medical necessity with full documentation, file an internal appeal, and request an external review if it is denied again.
How much does Wegovy cost without insurance in 2026?
As of October 2026, manufacturer self pay prices start around $149 per month for the lowest Wegovy pill dose and about $199 for initial Wegovy pen doses, rising at higher doses.
The Bottom Line
Coverage rules for GLP-1 medications were built to treat disease, not prevent it. When a plan requires diabetes or a heart attack before covering a drug proven to lower the risk of both, the logic is backward, and even the new Medicare GLP-1 Bridge ties eligibility to existing conditions below a BMI of 35.
You still have options. Know your plan's criteria, document your full clinical picture, appeal denials, and compare self pay prices that are far lower than they were in 2024. To find a prescriber who helps with prior authorization and appeals, compare vetted telehealth providers. Always consult your physician before starting, switching, or stopping any medication.